Biotech News

Mdxhealth to Release Second Quarter 2026 Financial Results on August 13

MDxHealth (MDXH)MDxHealthEarnings

Company to Host Conference Call with Live Q&A, August 13, 2026, at 4:30pm ET / 22:30 CET

IRVINE, California – July 30, 2026 ( GlobeNewswire ) – Mdxhealth SA (NASDAQ: MDXH), a leading precision diagnostics company, today announced it will release its financial results for the second quarter ended June 30, 2026, after market close on Thursday, August 13, 2026.

Title:Mdxhealth Presents Second Quarter 2026 Financial Results and Corporate Update Conference Call and Webcast
Date:August 13, 2026
Time:4:30pm ET/ 22:30 CET
Conference Call D ial-in Details:United States : 1-833-309-3473 Belgium : 0800 72 519 United Kingdom : 0808 101 1183
Conference ID:MDX2Q26
Webcast:https://viavid.webcasts.com/starthere.jsp?ei=1768432&tp_key=e5dee9dbef

The webcast should be accessed 15 minutes prior to the conference call start time. A replay of the webcast will be available following the conclusion of the live call and will be accessible on the Company’s website.

About Mdxhealth

Mdxhealth is a leading precision diagnostics company that provides actionable molecular information to personalize patient diagnosis and treatment. The Company’s tests, based on proprietary genomic, epigenomic, exosomal and other molecular technologies, assist physicians with the diagnosis and prognosis of prostate cancer and other urologic diseases. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.

For more information:

info@mdxhealth.com

LifeSci Advisors (IR & PR) John Fraunces, Managing Director Tel: +1 917 355 2395 [email protected]

Related news

MDxHealth

Precision Urologic Diagnostics MDxHealth provides molecular tests that support diagnosis, risk assessment, and treatment decisions in prostate cancer and other urologic diseases. Prostate Cancer Menu The company’s portfolio spans pre-biopsy risk assessment, tissue-based prognostic testing, and post-treatment monitoring, using genomic,...

Recent company news

Stock data

Close
0.44 USD
Market cap
32.93M USD
Exchange
NASDAQ
Sector
MedTech
Location
United States